Min Fang
Director/Board Member bij JINXIN FERTILITY GROUP LIMITED
Profiel
Min Fang is currently a Non-Executive Director at Jinxin Fertility Group Ltd., a Director at InSilico Medicine, Inc., and a Non-Executive Director at InSilico Medicine Cayman TopCo. Previously, Mr. Fang served as a Non-Executive Director at Hygeia Healthcare Holdings Co., Ltd.
Mr. Fang holds an MBA from Stanford University and completed undergraduate studies at Fudan University.
Actieve functies van Min Fang
Bedrijven | Functie | Begin |
---|---|---|
JINXIN FERTILITY GROUP LIMITED | Director/Board Member | 01-10-2018 |
InSilico Medicine, Inc.
InSilico Medicine, Inc. Packaged SoftwareTechnology Services Part of InSilico Medicine Hong Kong Ltd., InSilico Medicine, Inc. is a clinical stage biotechnology company based in New York, NY. InSilico Medicine is focused on generative models, reinforcement learning, and other modern machine learning techniques for the generation of new molecular structures with specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. The private company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. InSilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. The company was founded in 2014 by Aleksandr Aliper and Aleksandrs Zhavoronkov. Aleksandrs Zhavoronkov has been the CEO since 2014. | Director/Board Member | - |
Insilico Medicine Cayman TopCo
Insilico Medicine Cayman TopCo Miscellaneous Commercial ServicesCommercial Services InSilico Medicine Cayman TopCo is a holding company, which engages in the research and development of generative artificial intelligence (AI) driven therapeutic pipeline and software licensing. Its pipeline targets areas include high unmet needs, with a footprint in fibrosis, oncology, immunology, and other therapeutic areas. The company was founded by Alex Zhavoronkov on November 19, 2018 and is headquartered in Hong Kong. | Director/Board Member | 01-06-2021 |
Eerdere bekende functies van Min Fang
Bedrijven | Functie | Einde |
---|---|---|
HYGEIA HEALTHCARE HOLDINGS CO., LIMITED | Director/Board Member | 01-10-2021 |
Opleiding van Min Fang
Stanford University | Masters Business Admin |
Fudan University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
JINXIN FERTILITY GROUP LIMITED | Health Services |
HYGEIA HEALTHCARE HOLDINGS CO., LIMITED | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
InSilico Medicine, Inc.
InSilico Medicine, Inc. Packaged SoftwareTechnology Services Part of InSilico Medicine Hong Kong Ltd., InSilico Medicine, Inc. is a clinical stage biotechnology company based in New York, NY. InSilico Medicine is focused on generative models, reinforcement learning, and other modern machine learning techniques for the generation of new molecular structures with specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. The private company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. InSilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. The company was founded in 2014 by Aleksandr Aliper and Aleksandrs Zhavoronkov. Aleksandrs Zhavoronkov has been the CEO since 2014. | Technology Services |
Insilico Medicine Cayman TopCo
Insilico Medicine Cayman TopCo Miscellaneous Commercial ServicesCommercial Services InSilico Medicine Cayman TopCo is a holding company, which engages in the research and development of generative artificial intelligence (AI) driven therapeutic pipeline and software licensing. Its pipeline targets areas include high unmet needs, with a footprint in fibrosis, oncology, immunology, and other therapeutic areas. The company was founded by Alex Zhavoronkov on November 19, 2018 and is headquartered in Hong Kong. | Commercial Services |